Highly motivated and committed Medical Assistant with proven history of superior performance at individual, team and organizational levels. Strong ability to multitask and prioritize workloads with little or no supervision. Detail-oriented professional looking to bring medical background and team-building skills to deadline-driven environment.
IATA
Dangerous Goods Training
Research Experience
Medical Reasearch
• GS-US-292-0104: A Phase 3, Randomized, Double-Blind Study to evaluate the safety and efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus
Elvitegravir/Cobicistat//Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults. (Research Coordinator, 2013)
• GS-US-292-0109: A Phase 3, Open-Label Study to Evaluate Switching from a TDF- Containing Combination Regimen to a TAF- Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1, Positive Subjects. (Research Coordinator, 2013)
• GS-US-292-0\A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2013)
• GS-US-292-0119: A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alefenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1Positive Adults. (Research Coordinator, 2013)
• GS-US-311-1089: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. (Research Coordinator, 2014)
• GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Supressed, HIV-1Infected Subjects. (Research Coordinator, 2015)
• GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Supressed on Emtricitabine/Rilpivarine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). (Research Coordinator, 2015)
• GS-US-311-1717: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Supressed on Regimens Containing ABC/3TC. (Research Coordinator, 2015)
• GS-US-380-1489: A Phase 3, Randomized, double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2016)
• GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection. (Research Coordinator, 20016)itabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment – Naïve Adults. (Research Coordinator, 2013)
· GS-US-292-0109: A Phase 3, Open-Label Study to Evaluate Switching from a TDF- Containing Combination Regimen to a TAF- Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1, Positive Subjects. (Research Coordinator, 2013)
· GS-US-292-0111: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide Versus
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2013)
· GS-US-292-0119: A Phase 3 Open-Label Study to Evaluate Switching from Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alefenamide (E/C/F/TAF) Single Tablet Regimen (STR) plus Darunavir (DRV) in Treatment Experienced HIV-1Positive Adults. (Research Coordinator, 2013)
· GS-US-311-1089: A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF. (Research Coordinator, 2014)
· GS-US-366-1160: A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Supressed, HIV-1Infected Subjects. (Research Coordinator, 2015)
· GS-US-366-1216: A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of emtricitabine/Rilpivarine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Supressed on Emtricitabine/Rilpivarine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF). (Research Coordinator, 2015)
· GS-US-311-1717: A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Supressed on Regimens Containing ABC/3TC. (Research Coordinator, 2015)
· GS-US-380-1489: A Phase 3, Randomized, double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Abacavir/ Dolutegravir/ Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. (Research Coordinator, 2016)
· GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection. (Research Coordinator, 20016)
By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy
Resumes, and other information uploaded or provided by the user, are considered User Content governed by our Terms & Conditions. As such, it is not owned by us, and it is the user who retains ownership over such content.
Many factors go into creating a strong resume. Here are a few tweaks that could improve the score of this resume:
resume Strength
By clicking Customize This Resume, you agree to our Terms of Use and Privacy Policy